{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:59:43Z","timestamp":1794632383919,"version":"4.9.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Populations are ageing worldwide, with considerable time lived in ill-health, putting upwards pressure on healthcare budgets. Healthy ageing is defined as maintaining functional ability, including the ability to: meet basic needs; learn, grow and make decisions; be mobile; build and maintain relationships; and contribute to society. The risk and impact of infectious diseases increase with age due to immunosenescence. Vaccination can help to prevent disease in older adults, promoting healthy ageing and active lives. Herpes zoster (HZ) occurs when the varicella zoster virus is reactivated due to declining immunity. HZ is common, with a lifetime risk of one-third, and increases in incidence with age. HZ is associated with severe and intense pain, substantially affecting the functional status of patients as well as their overall health-related quality of life. HZ and its complications may result in prolonged morbidity, including persistent pain (post-herpetic neuralgia, PHN), hearing impairment, vision loss and increased risk of stroke and myocardial infarction. HZ and PHN are difficult to treat, substantiating the benefits of prevention. Vaccines to prevent HZ include a recombinant zoster vaccine (RZV). RZV has shown efficacy against the HZ burden of disease and HZ burden of interference on activities of daily living of over 90% in immunocompetent adults aged \u226550 years. Vaccine efficacy against HZ was maintained at over 70% at 10 years post-vaccination. Adult vaccination, including against HZ, has the potential to reduce burden of disease, thus helping to maintain functioning and quality of life to support healthy ageing in older adults.<\/jats:p>","DOI":"10.1038\/s41541-023-00757-0","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T05:02:25Z","timestamp":1701147745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Healthy ageing: Herpes zoster infection and the role of zoster vaccination"],"prefix":"10.1038","volume":"8","author":[{"given":"Desmond","family":"Curran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Mark","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lecrenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"757_CR1","unstructured":"World Bank Group. Life expectancy at birth, total (years) - European Union. https:\/\/data.worldbank.org\/indicator\/SP.DYN.LE00.IN?locations=EU (2021)."},{"key":"757_CR2","unstructured":"World Health Organization. The Global Health Observatory. Life Expectancy at Birth (years). Japan. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/life-expectancy-at-birth-(years) (2020)."},{"key":"757_CR3","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke, R., Cohen, J. I. & Oxman, M. N. Herpes Zoster Vaccines. J. Infect. Dis. 224, S429\u2013S442 (2021).","journal-title":"J. Infect. Dis."},{"key":"757_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12877-020-01894-0","volume":"20","author":"V Ho","year":"2020","unstructured":"Ho, V. et al. Healthcare utilisation in the last year of life in internal medicine, young-old versus old-old. BMC Geriatr. 20, 495 (2020).","journal-title":"BMC Geriatr."},{"key":"757_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40520-015-0314-7","volume":"27","author":"S Maggi","year":"2015","unstructured":"Maggi, S. et al. Preventing and managing herpes zoster: key actions to foster healthy aging. Aging Clin. Exp. Res. 27, 5\u201311 (2015).","journal-title":"Aging Clin. Exp. Res"},{"key":"757_CR6","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1016\/j.vaccine.2016.09.039","volume":"34","author":"C Raina MacIntyre","year":"2016","unstructured":"Raina MacIntyre, C. et al. Equity in disease prevention: Vaccines for the older adults - a national workshop, Australia 2014. Vaccine 34, 5463\u20135469 (2016).","journal-title":"Vaccine"},{"key":"757_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12979-021-00249-6","volume":"18","author":"B Weinberger","year":"2021","unstructured":"Weinberger, B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun. Ageing 18, 38 (2021).","journal-title":"Immun. Ageing"},{"key":"757_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40266-014-0193-1","volume":"31","author":"PO Lang","year":"2014","unstructured":"Lang, P. O. & Aspinall, R. Vaccination in the elderly: what can be recommended? Drugs Aging 31, 581\u2013599 (2014).","journal-title":"Drugs Aging"},{"key":"757_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","volume":"17","author":"SE Talbird","year":"2021","unstructured":"Talbird, S. E. et al. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum. Vaccin Immunother. 17, 332\u2013343 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"757_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1473-3099(20)30769-6","volume":"21","author":"W Yang","year":"2021","unstructured":"Yang, W. et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect. Dis. 21, 203\u2013212 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"757_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese, L., Standaert, B., Olivieri, A. & Curran, D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 17, 30 (2017).","journal-title":"BMC Geriatr."},{"key":"757_CR12","unstructured":"World Health Organization. Healthy ageing and functional ability. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/healthy-ageing-and-functional-ability (2020)."},{"key":"757_CR13","unstructured":"World Health Organization. UN Decade of Healthy Ageing 2021-2030. https:\/\/www.who.int\/initiatives\/decade-of-healthy-ageing (2022)."},{"key":"757_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/erv.10.25","volume":"9","author":"JP Baeyens","year":"2010","unstructured":"Baeyens, J. P. & Michel, J.-P. Immunization as a preventive healthcare strategy in older adults. Expert Rev. Vaccines 9, 1 (2010).","journal-title":"Expert Rev. Vaccines"},{"key":"757_CR15","doi-asserted-by":"publisher","first-page":"583019","DOI":"10.3389\/fimmu.2020.583019","volume":"11","author":"B Pereira","year":"2020","unstructured":"Pereira, B., Xu, X. N. & Akbar, A. N. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Front Immunol. 11, 583019 (2020).","journal-title":"Front Immunol."},{"key":"757_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","volume":"16","author":"SN Crooke","year":"2019","unstructured":"Crooke, S. N., Ovsyannikova, I. G., Poland, G. A. & Kennedy, R. B. Immunosenescence and human vaccine immune responses. Immun. Ageing 16, 25 (2019).","journal-title":"Immun. Ageing"},{"key":"757_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/07853890.2019.1588470","volume":"51","author":"TM Doherty","year":"2019","unstructured":"Doherty, T. M., Del Giudice, G. & Maggi, S. Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. Ann. Med 51, 128\u2013140 (2019).","journal-title":"Ann. Med"},{"key":"757_CR18","doi-asserted-by":"publisher","first-page":"579972","DOI":"10.3389\/fimmu.2020.579972","volume":"11","author":"MA Batista","year":"2020","unstructured":"Batista, M. A. et al. Inflammaging in Endemic Areas for Infectious Diseases. Front Immunol. 11, 579972 (2020).","journal-title":"Front Immunol."},{"key":"757_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/07853890.2017.1417632","volume":"50","author":"E de Gomensoro","year":"2018","unstructured":"de Gomensoro, E., Del Giudice, G. & Doherty, T. M. Challenges in adult vaccination. Ann. Med 50, 181\u2013192 (2018).","journal-title":"Ann. Med"},{"key":"757_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6501a1","volume":"65","author":"WW Williams","year":"2016","unstructured":"Williams, W. W. et al. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. MMWR Surveill. Summ. 65, 1\u201336 (2016).","journal-title":"MMWR Surveill. Summ."},{"key":"757_CR21","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1016\/j.vaccine.2020.04.027","volume":"38","author":"L Privor-Dumm","year":"2020","unstructured":"Privor-Dumm, L., Vasudevan, P., Kobayashi, K. & Gupta, J. Archetype analysis of older adult immunization decision-making and implementation in 34 countries. Vaccine 38, 4170\u20134182 (2020).","journal-title":"Vaccine"},{"key":"757_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00354-z","volume":"6","author":"B Laup\u00e8ze","year":"2021","unstructured":"Laup\u00e8ze, B., Del Giudice, G., Doherty, M. T. & Van der Most, R. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines 6, 93 (2021).","journal-title":"NPJ Vaccines"},{"key":"757_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40121-020-00312-7","volume":"9","author":"EP Chevalier-Cottin","year":"2020","unstructured":"Chevalier-Cottin, E. P. et al. Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases. Infect. Dis. Ther. 9, 467\u2013480 (2020).","journal-title":"Infect. Dis. Ther."},{"key":"757_CR24","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1016\/j.vaccine.2021.07.029","volume":"39","author":"J Carrico","year":"2021","unstructured":"Carrico, J. et al. Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population. Vaccine 39, 5187\u20135197 (2021).","journal-title":"Vaccine"},{"key":"757_CR25","unstructured":"Centers for Disease Control and Prevention. About Shingles (Herpes Zoster). https:\/\/www.cdc.gov\/shingles\/about\/index.html (2019)."},{"key":"757_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2198-y","volume":"17","author":"LK Chen","year":"2017","unstructured":"Chen, L. K. et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect. Dis. 17, 213 (2017).","journal-title":"BMC Infect. Dis."},{"key":"757_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran, D. et al. Meta-Regression of Herpes Zoster Incidence Worldwide. Infect. Dis. Ther. 11, 389\u2013403 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"757_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1477-7525-12-92","volume":"12","author":"M Serpell","year":"2014","unstructured":"Serpell, M. et al. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual. Life Outcomes 12, 92 (2014).","journal-title":"Health Qual. Life Outcomes"},{"key":"757_CR29","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bjd.19687","volume":"184","author":"HJ Forbes","year":"2021","unstructured":"Forbes, H. J. et al. Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data. Br. J. Dermatol 184, 1077\u20131084 (2021).","journal-title":"Br. J. Dermatol"},{"key":"757_CR30","first-page":"142","volume":"4","author":"CD Kalogeropoulos","year":"2015","unstructured":"Kalogeropoulos, C. D., Bassukas, I. D., Moschos, M. M. & Tabbara, K. F. Eye and Periocular Skin Involvement in Herpes Zoster Infection. Med. Hypothesis Discov. Innov. Ophthalmol. 4, 142\u2013156 (2015).","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"757_CR31","doi-asserted-by":"crossref","first-page":"233121651454136","DOI":"10.1177\/2331216514541361","volume":"18","author":"BE Cohen","year":"2014","unstructured":"Cohen, B. E., Durstenfeld, A. & Roehm, P. C. Viral causes of hearing loss: a review for hearing health professionals. Trends Hear 18, 2331216514541361 (2014).","journal-title":"Trends Hear"},{"key":"757_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40121-021-00581-w","volume":"11","author":"D Van Oorschot","year":"2022","unstructured":"Van Oorschot, D. et al. A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients\u2019 Health-Related Quality of Life. Infect. Dis. Ther. 11, 501\u2013516 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"757_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/gerona\/gly150","volume":"74","author":"D Curran","year":"2019","unstructured":"Curran, D. et al. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. J. Gerontol. A Biol. Sci. Med Sci. 74, 1231\u20131238 (2019).","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"key":"757_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/AJP.0000000000001129","volume":"39","author":"S Matthews","year":"2023","unstructured":"Matthews, S. et al. An Analysis of how Herpes Zoster Pain affects Health Related Quality of Life of Placebo subjects from Three Randomized Phase III Studies. Clin. J. Pain. 39, 386\u2013393 (2023).","journal-title":"Clin. J. Pain."},{"key":"757_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","volume":"23","author":"KE Schmader","year":"2007","unstructured":"Schmader, K. E. et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin. J. Pain. 23, 490\u2013496 (2007).","journal-title":"Clin. J. Pain."},{"key":"757_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","volume":"5","author":"PM Coplan","year":"2004","unstructured":"Coplan, P. M. et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J. Pain. 5, 344\u2013356 (2004).","journal-title":"J. Pain."},{"key":"757_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","volume":"153","author":"D Bouhassira","year":"2012","unstructured":"Bouhassira, D. et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 153, 342\u2013349 (2012).","journal-title":"Pain"},{"key":"757_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-402","volume":"14","author":"A Gater","year":"2014","unstructured":"Gater, A. et al. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect. Dis. 14, 402 (2014).","journal-title":"BMC Infect. Dis."},{"key":"757_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3395-z","volume":"18","author":"D Curran","year":"2018","unstructured":"Curran, D. et al. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect. Dis. 18, 496 (2018).","journal-title":"BMC Infect. Dis."},{"key":"757_CR40","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s12325-021-01717-7","volume":"38","author":"J D\u00edez-Domingo","year":"2021","unstructured":"D\u00edez-Domingo, J., Curran, D., Cambronero, M. D. R., Garcia-Martinez, J. A. & Matthews, S. Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study. Adv. Ther. 38, 3325\u20133341 (2021).","journal-title":"Adv. Ther."},{"key":"757_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0637-6","volume":"14","author":"H Bricout","year":"2014","unstructured":"Bricout, H. et al. Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009\u20132010): a GP-based prospective cohort study. BMC Infect. Dis. 14, 637 (2014).","journal-title":"BMC Infect. Dis."},{"key":"757_CR42","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.6061\/clinics\/2018\/e243","volume":"73","author":"J Toniolo-Neto","year":"2018","unstructured":"Toniolo-Neto, J. et al. Measuring herpes zoster disease burden in Sao Paulo, Brazil: a clinico-epidemiological single-center study. Clin. (Sao Paulo) 73, e243 (2018).","journal-title":"Clin. (Sao Paulo)"},{"key":"757_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40261-017-0581-5","volume":"38","author":"A Mizukami","year":"2018","unstructured":"Mizukami, A. et al. Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study. Clin. Drug Investig. 38, 29\u201337 (2018).","journal-title":"Clin. Drug Investig."},{"key":"757_CR44","doi-asserted-by":"publisher","first-page":"749698","DOI":"10.1155\/2014\/749698","volume":"2014","author":"T Weinke","year":"2014","unstructured":"Weinke, T., Glogger, A., Bertrand, I. & Lukas, K. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. ScientificWorldJournal 2014, 749698 (2014).","journal-title":"ScientificWorldJournal"},{"key":"757_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","volume":"26","author":"TA Lieu","year":"2008","unstructured":"Lieu, T. A. et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 26, 235\u2013249 (2008).","journal-title":"Pharmacoeconomics"},{"key":"757_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier, N. et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev. Vaccines 17, 619\u2013634 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"757_CR47","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","volume":"30","author":"M Drolet","year":"2012","unstructured":"Drolet, M. et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine 30, 2047\u20132050 (2012).","journal-title":"Vaccine"},{"key":"757_CR48","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/papr.12518","volume":"17","author":"AJM van Wijck","year":"2017","unstructured":"van Wijck, A. J. M. & Aerssens, Y. R. Pain, Itch, Quality of Life, and Costs after Herpes Zoster. Pain. Pr. 17, 738\u2013746 (2017).","journal-title":"Pain. Pr."},{"key":"757_CR49","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/infdis\/jiy385","volume":"218","author":"C Warren-Gash","year":"2018","unstructured":"Warren-Gash, C. Herpes Zoster: Epidemiological Links With Stroke and Myocardial Infarction. J. Infect. Dis. 218, S102\u2013S106 (2018).","journal-title":"J. Infect. Dis."},{"key":"757_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.virol.2004.10.047","volume":"332","author":"L Zerboni","year":"2005","unstructured":"Zerboni, L. et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka\/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332, 337\u2013346 (2005).","journal-title":"Virology"},{"key":"757_CR51","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/infdis\/jiy383","volume":"218","author":"A Weinberg","year":"2018","unstructured":"Weinberg, A. et al. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J. Infect. Dis. 218, S81\u2013S87 (2018).","journal-title":"J. Infect. Dis."},{"key":"757_CR52","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/infdis\/jiab580","volume":"225","author":"MJ Johnson","year":"2022","unstructured":"Johnson, M. J. et al. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. J. Infect. Dis. 225, 1477\u20131481 (2022).","journal-title":"J. Infect. Dis."},{"key":"757_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson, T. C. et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \u226519 Years: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022. Morbidity Mortal. Wkly. Rep. 71, 80\u201384 (2022).","journal-title":"Morbidity Mortal. Wkly. Rep."},{"key":"757_CR54","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","volume":"20","author":"R Parikh","year":"2021","unstructured":"Parikh, R., Widenmaier, R. & Lecrenier, N. A practitioner\u2019s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev. Vaccines 20, 1065\u20131075 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"757_CR55","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087\u20132096 (2015).","journal-title":"N. Engl. J. Med"},{"key":"757_CR56","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham, A. L. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N. Engl. J. Med. 375, 1019\u20131032 (2016).","journal-title":"N. Engl. J. Med"},{"key":"757_CR57","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1016\/j.vaccine.2019.09.028","volume":"37","author":"DO Willer","year":"2019","unstructured":"Willer, D. O. et al. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine 37, 6262\u20136267 (2019).","journal-title":"Vaccine"},{"key":"757_CR58","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","volume":"15","author":"L Oostvogels","year":"2019","unstructured":"Oostvogels, L. et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum. Vaccin. Immunother. 15, 2865\u20132872 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"757_CR59","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1080\/21645515.2020.1859321","volume":"17","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults \u2265 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum. Vaccin Immunother. 17, 2050\u20132057 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"757_CR60","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham, A. L. et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J. Infect. Dis. 217, 1750\u20131760 (2018).","journal-title":"J. Infect. Dis."},{"key":"757_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"36","author":"H Lal","year":"2018","unstructured":"Lal, H. et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine 36, 148\u2013154 (2018).","journal-title":"Vaccine"},{"key":"757_CR62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jgs.16917","volume":"69","author":"D Curran","year":"2021","unstructured":"Curran, D. et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J. Am. Geriatr. Soc. 69, 744\u2013752 (2021).","journal-title":"J. Am. Geriatr. Soc."},{"key":"757_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas, A. et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 322, 123\u2013133 (2019).","journal-title":"JAMA"},{"key":"757_CR64","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew, A. F. et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect. Dis. 19, 988\u20131000 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"757_CR65","doi-asserted-by":"publisher","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova, A. et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect. Dis. 9, ofac485 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"757_CR66","first-page":"2780","volume":"14","author":"PK Ghaswalla","year":"2018","unstructured":"Ghaswalla, P. K. et al. Hepatitis A, B, and A\/B vaccination series completion among US adults: A claims-based analysis. Hum. Vaccines Immunotherapeutics 14, 2780\u20132785 (2018).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"757_CR67","unstructured":"Cubanski, J., Neuman, T. & Damico, A. Who Didn\u2019t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines. https:\/\/www.kff.org\/medicare\/issue-brief\/who-didnt-get-a-second-shingrix-shot-implications-for-multidose-covid-19-vaccines\/ (2020)."},{"key":"757_CR68","unstructured":"Dooling, K. Herpes zoster vaccines: update. https:\/\/stacks.cdc.gov\/view\/cdc\/78105 (2019)."},{"key":"757_CR69","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","volume":"37","author":"M Lopez-Fauqued","year":"2019","unstructured":"Lopez-Fauqued, M. et al. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine 37, 2482\u20132493 (2019).","journal-title":"Vaccine"},{"key":"757_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vaccine.2020.10.029","volume":"39","author":"J Ocran-Appiah","year":"2021","unstructured":"Ocran-Appiah, J. et al. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. Vaccine 39, 6\u201310 (2021).","journal-title":"Vaccine"},{"key":"757_CR71","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","volume":"181","author":"R Goud","year":"2021","unstructured":"Goud, R. et al. Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern Med. 181, 1623\u20131630 (2021).","journal-title":"JAMA Intern Med"},{"key":"757_CR72","unstructured":"Shingrix. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf (2022)."},{"key":"757_CR73","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/j.pain.0000000000002760","volume":"164","author":"JH Kim","year":"2023","unstructured":"Kim, J. H. et al. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. Pain 164, 741\u2013748 (2023).","journal-title":"Pain"},{"key":"757_CR74","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","volume":"25","author":"D Curran","year":"2019","unstructured":"Curran, D. et al. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). Biol. Blood Marrow Transpl. 25, 2474\u20132481 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"757_CR75","first-page":"1567","volume":"26","author":"BJ Patterson","year":"2020","unstructured":"Patterson, B. J. et al. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J. Manag Care Spec. Pharm. 26, 1567\u20131575 (2020).","journal-title":"J. Manag Care Spec. Pharm."},{"key":"757_CR76","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1080\/21645515.2021.1932216","volume":"17","author":"C Lee","year":"2021","unstructured":"Lee, C. et al. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum. Vaccin. Immunother. 17, 3735\u20133746 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"757_CR77","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","volume":"15","author":"D Curran","year":"2019","unstructured":"Curran, D. et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum. Vaccin. Immunother. 15, 765\u2013771 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"757_CR78","doi-asserted-by":"publisher","first-page":"2168952","DOI":"10.1080\/21645515.2023.2168952","volume":"19","author":"N Giannelos","year":"2023","unstructured":"Giannelos, N., Ng, C. & Curran, D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Hum. Vaccin. Immunother. 19, 2168952 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"757_CR79","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran, D. et al. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum. Vaccin. Immunother. 17, 5296\u20135303 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"757_CR80","doi-asserted-by":"publisher","first-page":"e12293","DOI":"10.1002\/trc2.12293","volume":"8","author":"C Schnier","year":"2022","unstructured":"Schnier, C., Janbek, J., Lathe, R. & Haas, J. Reduced dementia incidence after varicella zoster vaccination in Wales 2013\u20132020. Alzheimer\u2019s Dement.: Transl. Res. Clin. Interventions 8, e12293 (2022).","journal-title":"Alzheimer\u2019s Dement.: Transl. Res. Clin. Interventions"},{"key":"757_CR81","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JAD-221231","volume":"95","author":"K Harris","year":"2023","unstructured":"Harris, K. et al. The impact of routine vaccinations on alzheimer\u2019s disease risk in persons 65 years and older: a claims-based cohort study using propensity score matching. J. Alzheimer\u2019s Dis. 95, 703\u2013718 (2023).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"757_CR82","unstructured":"Sustainable Development Solutions Network. World Happiness Report. https:\/\/worldhappiness.report\/ed\/2021\/ (2021)."},{"key":"757_CR83","unstructured":"McKinsey Health Institute. Adding years to life and life to years. https:\/\/www.mckinsey.com\/mhi\/our-insights\/adding-years-to-life-and-life-to-years#\/ (2022)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00757-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T06:07:24Z","timestamp":1701151644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00757-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00757-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C., M.D., N.L. and T.B. are employed by\/hold shares in GSK. N.L. received grants and declared patents from GSK. All authors declare no other financial and non-financial relationships and activities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}